Clinical Trials
29 trials68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
Mayo Clinic
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection
AHS Cancer Control Alberta
Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Jonsson Comprehensive Cancer Center
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
OHSU Knight Cancer Institute
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
University of California, San Francisco
Brivanib Metastatic Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
University of California, San Francisco
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
University of Wisconsin, Madison
A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer
AHS Cancer Control Alberta
HX4-cervix
Maastricht Radiation Oncology
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
British Columbia Cancer Agency
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
SWOG Cancer Research Network
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
National Institutes of Health Clinical Center (CC)
Imaging Studies of Kidney Cancer Using 18F-VM4-037
National Institutes of Health Clinical Center (CC)
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma
AHS Cancer Control Alberta
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Vanderbilt-Ingram Cancer Center
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)